{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T20:54:19Z","timestamp":1791147259051,"version":"4.1.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["nanomedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.nano.2014.12.003","type":"journal-article","created":{"date-parts":[[2015,1,14]],"date-time":"2015-01-14T03:53:14Z","timestamp":1421207594000},"page":"1003-1018","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["Therapeutic applications of nanomedicine in autoimmune diseases: From immunosuppression to tolerance induction"],"prefix":"10.1016","volume":"11","author":[{"given":"Marjan","family":"Gharagozloo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slawomir","family":"Majewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7437-7917","authenticated-orcid":false,"given":"Marianna","family":"Foldvari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.nano.2014.12.003_bb0005","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s12016-013-8355-1","article-title":"Clinical guidelines and definitions of autoinflammatory diseases: contrasts and comparisons with autoimmunity-a comprehensive review","volume":"45","author":"Zen","year":"2013","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.nano.2014.12.003_bb0010","series-title":"Fundamental Immunology","author":"Paul","year":"2008"},{"key":"10.1016\/j.nano.2014.12.003_bb0015","series-title":"Janeway's immunobiology: Garland Science","author":"Murphy","year":"2012"},{"key":"10.1016\/j.nano.2014.12.003_bb0020","series-title":"Immunology","author":"Male","year":"2012"},{"issue":"4","key":"10.1016\/j.nano.2014.12.003_bb0025","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.clindermatol.2013.01.005","article-title":"Pemphigus: associations and management guidelines: facts and controversies","volume":"31","author":"Ruocco","year":"2013","journal-title":"Clin Dermatol"},{"issue":"1","key":"10.1016\/j.nano.2014.12.003_bb0030","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1517\/14728214.8.1.47","article-title":"Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases","volume":"8","author":"Kovarik","year":"2003","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.nano.2014.12.003_bb0035","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1741-7015-11-88","article-title":"Biologic therapy for autoimmune diseases: an update","volume":"11","author":"Rosman","year":"2013","journal-title":"BMC Med"},{"issue":"6","key":"10.1016\/j.nano.2014.12.003_bb0040","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cell.2010.02.043","article-title":"Anti-inflammatory Agents: Present and Future","volume":"140","author":"Dinarello","year":"2010","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.nano.2014.12.003_bb0045","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00280-012-2062-0","article-title":"A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis","volume":"71","author":"Abolmaali","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"10.1016\/j.nano.2014.12.003_bb0050","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3109\/08916931003674758","article-title":"Development of small-molecule therapies for autoimmune diseases","volume":"43","author":"Burli","year":"2010","journal-title":"Autoimmunity"},{"issue":"9","key":"10.1016\/j.nano.2014.12.003_bb0055","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1517\/17425247.5.9.1027","article-title":"Drug delivery systems for the treatment of rheumatoid arthritis","volume":"5","author":"Tarner","year":"2008","journal-title":"Expert Opin Drug Deliv"},{"issue":"4","key":"10.1016\/j.nano.2014.12.003_bb0060","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1021\/mp2000742","article-title":"Liposomal drug formulations in the treatment of rheumatoid arthritis","volume":"8","author":"van den Hoven","year":"2011","journal-title":"Mol Pharm"},{"issue":"8","key":"10.1016\/j.nano.2014.12.003_bb0065","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2217\/nnm.12.86","article-title":"Nanobiotechnology-based strategies for crossing the blood-brain barrier","volume":"7","author":"Jain","year":"2012","journal-title":"Nanomedicine"},{"issue":"4","key":"10.1016\/j.nano.2014.12.003_bb0070","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4161\/derm.1.4.9501","article-title":"Nanoparticles and their interactions with the dermal barrier","volume":"1","author":"Schneider","year":"2009","journal-title":"Dermatol Endocrinol"},{"issue":"1-2","key":"10.1016\/j.nano.2014.12.003_bb0075","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.imlet.2013.12.018","article-title":"Nanomedicine in autoimmunity","volume":"158","author":"Clemente-Casares","year":"2014","journal-title":"Immunol Lett"},{"issue":"1","key":"10.1016\/j.nano.2014.12.003_bb0080","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"10.1016\/j.nano.2014.12.003_bb0085","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1124\/jpet.111.185884","article-title":"Arthritic joint-targeting small interfering RNA-encapsulated liposome: implication for treatment strategy for rheumatoid arthritis","volume":"340","author":"Komano","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"10.1016\/j.nano.2014.12.003_bb0090","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/gt.2011.159","article-title":"Effect of topical interferon-gamma gene therapy using gemini nanoparticles on pathophysiological markers of cutaneous scleroderma in Tsk\/+ mice","volume":"19","author":"Badea","year":"2012","journal-title":"Gene Ther"},{"issue":"5","key":"10.1016\/j.nano.2014.12.003_bb0095","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/wnan.1185","article-title":"Peptide delivery using phospholipid micelles","volume":"4","author":"Banerjee","year":"2012","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"issue":"7","key":"10.1016\/j.nano.2014.12.003_bb0100","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1002\/art.11140","article-title":"Complete remission of experimental arthritis by joint targeting of glucocorticoids with long\u2010circulating liposomes","volume":"48","author":"Metselaar","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.nano.2014.12.003_bb0105","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/1759720X13480280","article-title":"Latest advances in connective tissue disorders","volume":"5","author":"Rao","year":"2013","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"12","key":"10.1016\/j.nano.2014.12.003_bb0110","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nnano.2007.387","article-title":"Nanocarriers as an emerging platform for cancer therapy","volume":"2","author":"Peer","year":"2007","journal-title":"Nat Nanotechnol"},{"issue":"2","key":"10.1016\/j.nano.2014.12.003_bb0115","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2249.2003.02144.x","article-title":"Cytokine\u2010based immunointervention in the treatment of autoimmune diseases","volume":"132","author":"Adorini","year":"2003","journal-title":"Clin Exp Immunol"},{"issue":"9","key":"10.1016\/j.nano.2014.12.003_bb0120","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nrd2805","article-title":"Averting inflammation by targeting the cytokine environment","volume":"9","author":"Kopf","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.nano.2014.12.003_bb0125","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1517\/17425247.2014.863872","article-title":"Latent cytokines for targeted therapy of inflammatory disorders","volume":"11","author":"Mullen","year":"2014","journal-title":"Expert Opin Drug Deliv"},{"issue":"3","key":"10.1016\/j.nano.2014.12.003_bb0130","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/1947603510392914","article-title":"Gene therapy for cartilage repair","volume":"2","author":"Madry","year":"2011","journal-title":"Cartilage"},{"key":"10.1016\/j.nano.2014.12.003_bb0135","doi-asserted-by":"crossref","first-page":"782041","DOI":"10.1155\/2013\/782041","article-title":"Recent developments in nanoparticle-based siRNA delivery for cancer therapy","volume":"2013","author":"Lee","year":"2013","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.nano.2014.12.003_bb0140","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/978351","article-title":"Application of liposomes in treatment of rheumatoid arthritis: Quo vadis","author":"Kapoor","year":"2014","journal-title":"Scientific World Journal"},{"issue":"6","key":"10.1016\/j.nano.2014.12.003_bb0145","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1002\/art.21876","article-title":"Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor alpha in experimental arthritis","volume":"54","author":"Khoury","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nano.2014.12.003_bb0150","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2147\/IJN.S25310","article-title":"Investigation of nano lipid vesicles of methotrexate for anti-rheumatoid activity","volume":"7","author":"Prabhu","year":"2012","journal-title":"Int J Nanomedicine"},{"issue":"8","key":"10.1016\/j.nano.2014.12.003_bb0155","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1002\/art.23660","article-title":"Efficient suppression of murine arthritis by combined anticytokine small interfering RNA lipoplexes","volume":"58","author":"Khoury","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.nano.2014.12.003_bb0160","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jbspin.2010.08.017","article-title":"Cell and cytokine imbalances in rheumatoid synovitis","volume":"78","author":"Boissier","year":"2011","journal-title":"Joint Bone Spine"},{"issue":"1-2","key":"10.1016\/j.nano.2014.12.003_bb0165","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijpharm.2012.09.017","article-title":"Assembled nanomedicines as efficient and safe therapeutics for articular inflammation","volume":"439","author":"Che","year":"2012","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1016\/j.nano.2014.12.003_bb0170","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/mt.2008.220","article-title":"Chitosan\/siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model","volume":"17","author":"Howard","year":"2009","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.nano.2014.12.003_bb0175","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jconrel.2012.05.004","article-title":"MRI-assessed therapeutic effects of locally administered PLGA nanoparticles loaded with anti-inflammatory siRNA in a murine arthritis model","volume":"161","author":"te Boekhorst","year":"2012","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/j.nano.2014.12.003_bb0180","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jconrel.2013.04.021","article-title":"Topical delivery of anti-TNFalpha siRNA and capsaicin via novel lipid-polymer hybrid nanoparticles efficiently inhibits skin inflammation in vivo","volume":"170","author":"Desai","year":"2013","journal-title":"J Control Release"},{"issue":"4","key":"10.1016\/j.nano.2014.12.003_bb0185","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.trsl.2013.01.002","article-title":"Arthritis gene therapy and its tortuous path into the clinic","volume":"161","author":"Evans","year":"2013","journal-title":"Transl Res"},{"issue":"1","key":"10.1016\/j.nano.2014.12.003_bb0190","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.gt.3301111","article-title":"The application of gene therapy in autoimmune diseases","volume":"7","author":"Seroogy","year":"2000","journal-title":"Gene Ther"},{"issue":"28","key":"10.1016\/j.nano.2014.12.003_bb0195","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1002\/adma.201200446","article-title":"Engineering nano- and microparticles to tune immunity","volume":"24","author":"Moon","year":"2012","journal-title":"Adv Mater"},{"issue":"1","key":"10.1016\/j.nano.2014.12.003_bb0200","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11095-008-9710-4","article-title":"Poly (lactide-co-glycolide)-polymethacrylate nanoparticles for intramuscular delivery of plasmid encoding interleukin-10 to prevent autoimmune diabetes in mice","volume":"26","author":"Basarkar","year":"2009","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.nano.2014.12.003_bb0205","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2174\/156652308783688491","article-title":"Gemini surfactants: a new family of building blocks for non-viral gene delivery systems","volume":"8","author":"Wettig","year":"2008","journal-title":"Curr Gene Ther"},{"issue":"9","key":"10.1016\/j.nano.2014.12.003_bb0210","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1002\/jgm.763","article-title":"In vivo cutaneous interferon-gamma gene delivery using novel dicationic (gemini) surfactant-plasmid complexes","volume":"7","author":"Badea","year":"2005","journal-title":"J Gene Med"},{"issue":"3","key":"10.1016\/j.nano.2014.12.003_bb0215","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ejpb.2007.01.002","article-title":"Topical non-invasive gene delivery using gemini nanoparticles in interferon-\u03b3-deficient mice","volume":"65","author":"Badea","year":"2007","journal-title":"Eur J Pharm Biopharm"},{"issue":"4","key":"10.1016\/j.nano.2014.12.003_bb0220","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3899\/jrheum.100055","article-title":"Arthritis gene therapy trials reach phase II","volume":"37","author":"Evans","year":"2010","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1016\/j.nano.2014.12.003_bb0225","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/cbic.200300663","article-title":"Spiegelmers: biostable aptamers","volume":"4","author":"Eulberg","year":"2003","journal-title":"Chembiochem"},{"issue":"1-2","key":"10.1016\/j.nano.2014.12.003_bb0230","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ejps.2012.10.014","article-title":"Therapeutic RNA aptamers in clinical trials","volume":"48","author":"Sundaram","year":"2013","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"10.1016\/j.nano.2014.12.003_bb0235","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1042\/BJ20131422","article-title":"Identification and characterization of a mirror-image oligonucleotide that binds and neutralizes Sphingosine-1-Phosphate, a central mediator of angiogenesis","volume":"462","author":"Purschke","year":"2014","journal-title":"Biochem J"},{"key":"10.1016\/j.nano.2014.12.003_bb0240","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/978-1-61779-430-8_17","article-title":"Expanding human T regulatory cells with the mTOR-inhibitor rapamycin","volume":"821","author":"Battaglia","year":"2012","journal-title":"Methods Mol Biol"},{"issue":"9","key":"10.1016\/j.nano.2014.12.003_bb0245","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3324\/haematol.2011.041483","article-title":"Stability of human rapamycin-expanded CD4+ CD25+ T regulatory cells","volume":"96","author":"Tresoldi","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.nano.2014.12.003_bb0250","doi-asserted-by":"crossref","DOI":"10.4161\/trns.28263","article-title":"mTOR signaling and transcriptional regulation in T lymphocytes","volume":"5","author":"Zeng","year":"2014","journal-title":"Transcription"},{"issue":"6","key":"10.1016\/j.nano.2014.12.003_bb0255","doi-asserted-by":"crossref","first-page":"a015545","DOI":"10.1101\/cshperspect.a015545","article-title":"Regulatory Cells and Transplantation Tolerance","volume":"3","author":"Cobbold","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"6","key":"10.1016\/j.nano.2014.12.003_bb0260","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1021\/mp200394t","article-title":"Nanomedicine(s) under the microscope","volume":"8","author":"Duncan","year":"2011","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.nano.2014.12.003_bb0265","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/nano.2007.2.1.25","article-title":"Nanomedicines in renal transplant rejection\u2013focus on sirolimus","volume":"2","author":"Shen","year":"2007","journal-title":"Int J Nanomedicine"},{"issue":"3","key":"10.1016\/j.nano.2014.12.003_bb0270","first-page":"295","article-title":"Nanocrystal technology, drug delivery and clinical applications","volume":"3","author":"Junghanns","year":"2008","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.nano.2014.12.003_bb0275","first-page":"131","article-title":"PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update","volume":"7","author":"Reuss","year":"2013","journal-title":"Biologics"},{"issue":"7","key":"10.1016\/j.nano.2014.12.003_bb0280","first-page":"657","article-title":"Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study","volume":"13","author":"Calabresi","year":"2014"},{"issue":"3","key":"10.1016\/j.nano.2014.12.003_bb0285","first-page":"415","article-title":"Certolizumab for rheumatoid arthritis","volume":"32","author":"Markatseli","year":"2014","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.nano.2014.12.003_bb0290","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40265-013-0009-3","article-title":"Certolizumab Pegol","volume":"73","author":"Deeks","year":"2013","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.nano.2014.12.003_bb0295","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/nano.2007.2.1.39","article-title":"Targeting nanomedicines in the treatment of Crohn\u2019s disease: focus on certolizumab pegol (CDP870)","volume":"2","author":"Dinesen","year":"2007","journal-title":"Int J Nanomedicine"},{"issue":"3","key":"10.1016\/j.nano.2014.12.003_bb0300","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jconrel.2013.07.016","article-title":"A rapamycin-binding protein polymer nanoparticle shows potent therapeutic activity in suppressing autoimmune dacryoadenitis in a mouse model of Sj\u00f6gren's syndrome","volume":"171","author":"Shah","year":"2013","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/j.nano.2014.12.003_bb0305","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1096\/fj.12-213975","article-title":"Liposome-encapsulated peptides protect against experimental allergic encephalitis","volume":"27","author":"Belogurov","year":"2013","journal-title":"FASEB J"},{"issue":"4","key":"10.1016\/j.nano.2014.12.003_bb0310","doi-asserted-by":"crossref","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2013006955","article-title":"Peptide and protein delivery using new drug delivery systems","volume":"30","author":"Jain","year":"2013","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"issue":"4","key":"10.1016\/j.nano.2014.12.003_bb0315","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1021\/mp200614q","article-title":"Vaccine-like controlled-release delivery of an immunomodulating peptide to treat experimental autoimmune encephalomyelitis","volume":"9","author":"Buyuktimkin","year":"2012","journal-title":"Mol Pharm"},{"issue":"2","key":"10.1016\/j.nano.2014.12.003_bb0320","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jconrel.2009.09.002","article-title":"Immune response to controlled release of immunomodulating peptides in a murine experimental autoimmune encephalomyelitis (EAE) model","volume":"141","author":"Zhao","year":"2010","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/j.nano.2014.12.003_bb0325","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00726-011-1184-8","article-title":"Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions","volume":"45","author":"Delgado","year":"2013","journal-title":"Amino Acids"},{"issue":"4","key":"10.1016\/j.nano.2014.12.003_bb0330","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s11095-010-0330-4","article-title":"Actively targeted low-dose camptothecin as a safe, long-acting, disease-modifying nanomedicine for rheumatoid arthritis","volume":"28","author":"Koo","year":"2011","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.nano.2014.12.003_bb0335","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1021\/mp300539f","article-title":"Novel, biocompatible, and disease modifying VIP nanomedicine for rheumatoid arthritis","volume":"10","author":"Sethi","year":"2013","journal-title":"Mol Pharm"},{"issue":"10","key":"10.1016\/j.nano.2014.12.003_bb0340","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/nbt1006-1211","article-title":"The emerging nanomedicine landscape","volume":"24","author":"Wagner","year":"2006","journal-title":"Nat Biotechnol"},{"issue":"5","key":"10.1016\/j.nano.2014.12.003_bb0345","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.autrev.2012.09.005","article-title":"The mechanism of action of glatiramer acetate in multiple sclerosis and beyond","volume":"12","author":"Aharoni","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.nano.2014.12.003_bb0350","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.autrev.2013.10.012","article-title":"Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature","volume":"13","author":"Mahurkar","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.nano.2014.12.003_bb0355","first-page":"1525","article-title":"Exosome mimetics: a novel class of drug delivery systems","volume":"7","author":"Kooijmans","year":"2012","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.nano.2014.12.003_bb0360","first-page":"573528","article-title":"Immunosuppressive exosomes: a new approach for treating arthritis","volume":"2012","author":"Yang","year":"2012","journal-title":"Int J Rheum"},{"issue":"1","key":"10.1016\/j.nano.2014.12.003_bb0365","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s10753-012-9539-1","article-title":"Immature dendritic cell-derived exosomes: A promise subcellular vaccine for autoimmunity","volume":"36","author":"Yin","year":"2013","journal-title":"Inflammation"},{"issue":"3","key":"10.1016\/j.nano.2014.12.003_bb0370","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.pathophys.2005.07.011","article-title":"Animal models of rheumatoid arthritis and their relevance to human disease","volume":"12","author":"Kannan","year":"2005","journal-title":"Pathophysiology"},{"issue":"4","key":"10.1016\/j.nano.2014.12.003_bb0375","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.4049\/jimmunol.179.4.2242","article-title":"Effective treatment of inflammatory disease models with exosomes derived from dendritic cells genetically modified to express IL-4","volume":"179","author":"Kim","year":"2007","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.nano.2014.12.003_bb0380","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/cr.2011.196","article-title":"Immunosuppressive exosomes from TGF-\u03b21 gene-modified dendritic cells attenuate Th17-mediated inflammatory autoimmune disease by inducing regulatory T cells","volume":"22","author":"Cai","year":"2011","journal-title":"Cell Res"},{"issue":"1","key":"10.1016\/j.nano.2014.12.003_bb0385","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.0105-2896.2005.00280.x","article-title":"Oral tolerance","volume":"206","author":"Faria","year":"2005","journal-title":"Immunol Rev"},{"issue":"08","key":"10.1016\/j.nano.2014.12.003_bb0390","first-page":"21","article-title":"Controlled Drug Delivery Approaches for Rheumatoid Arthritis","volume":"2","author":"Kaur","year":"2012","journal-title":"J Appl Pharm Sci"},{"issue":"1","key":"10.1016\/j.nano.2014.12.003_bb0395","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/10611860701725191","article-title":"Enhanced efficacy of diclofenac sodium-loaded lipogelosome formulation in intra-articular treatment of rheumatoid arthritis","volume":"16","author":"T\u00fcrker","year":"2008","journal-title":"J Drug Target"},{"key":"10.1016\/j.nano.2014.12.003_bb0400","article-title":"The Development of Targeted Drug Delivery Systems for Rheumatoid Arthritis Treatment","author":"Bader","year":"2012"},{"issue":"4","key":"10.1016\/j.nano.2014.12.003_bb0405","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/art.10198","article-title":"Suppression of collagen-induced arthritis by single administration of poly(lactic-co-glycolic acid) nanoparticles entrapping type II collagen: a novel treatment strategy for induction of oral tolerance","volume":"46","author":"Kim","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.nano.2014.12.003_bb0410","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S0149-2918(00)80005-3","article-title":"Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis","volume":"21","author":"Goldenberg","year":"1999","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.nano.2014.12.003_bb0415","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.nano.2010.01.001","article-title":"Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies","volume":"6","author":"Klippstein","year":"2010","journal-title":"Nanomedicine"},{"issue":"188","key":"10.1016\/j.nano.2014.12.003_bb0420","doi-asserted-by":"crossref","first-page":"188ra75","DOI":"10.1126\/scitranslmed.3006168","article-title":"Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis","volume":"5","author":"Lutterotti","year":"2013","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.nano.2014.12.003_bb0425","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nrd3916","article-title":"Immunomodulators: particulate promotion of tolerance","volume":"12","author":"Tse","year":"2013","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"10.1016\/j.nano.2014.12.003_bb0430","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/nbt.2434","article-title":"Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis","volume":"30","author":"Getts","year":"2012","journal-title":"Nat Biotechnol"},{"issue":"3","key":"10.1016\/j.nano.2014.12.003_bb0435","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1021\/nn405033r","article-title":"A biodegradable nanoparticle platform for the induction of antigen-specific immune tolerance for treatment of autoimmune disease","volume":"8","author":"Hunter","year":"2014","journal-title":"ACS Nano"},{"issue":"4","key":"10.1016\/j.nano.2014.12.003_bb0440","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1900\/RDS.2012.9.319","article-title":"Tolerance strategies employing antigen-coupled apoptotic cells and carboxylated PLG nanoparticles for the treatment of type 1 diabetes","volume":"9","author":"Prasad","year":"2012","journal-title":"Rev Diabet Stud"},{"issue":"2","key":"10.1016\/j.nano.2014.12.003_bb0445","doi-asserted-by":"crossref","first-page":"a007773","DOI":"10.1101\/cshperspect.a007773","article-title":"Antigen-specific therapeutic approaches in Type 1 diabetes","volume":"2","author":"Clemente-Casares","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"4","key":"10.1016\/j.nano.2014.12.003_bb0450","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.immuni.2010.03.015","article-title":"Reversal of autoimmunity by boosting memory-like autoregulatory T cells","volume":"32","author":"Tsai","year":"2010","journal-title":"Immunity"},{"issue":"7042","key":"10.1016\/j.nano.2014.12.003_bb0455","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nature03727","article-title":"Design of effective immunotherapy for human autoimmunity","volume":"435","author":"Feldmann","year":"2005","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.nano.2014.12.003_bb0460","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.molimm.2013.08.006","article-title":"A novel nanoparticle containing MOG peptide with BTLA induces T cell tolerance and prevents multiple sclerosis","volume":"57","author":"Yuan","year":"2014","journal-title":"Mol Immunol"},{"issue":"5","key":"10.1016\/j.nano.2014.12.003_bb0465","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2217\/imt.13.25","article-title":"Nanoparticles for the induction of antigen-specific Tregs","volume":"5","author":"Quintana","year":"2013","journal-title":"Immunotherapy"},{"issue":"9","key":"10.1016\/j.nano.2014.12.003_bb0470","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/ni.1915","article-title":"Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells","volume":"11","author":"Gandhi","year":"2010","journal-title":"Nat Immunol"},{"issue":"28","key":"10.1016\/j.nano.2014.12.003_bb0475","doi-asserted-by":"crossref","first-page":"11270","DOI":"10.1073\/pnas.1120611109","article-title":"Nanoparticle-mediated codelivery of myelin antigen and a tolerogenic small molecule suppresses experimental autoimmune encephalomyelitis","volume":"109","author":"Yeste","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.nano.2014.12.003_bb0480","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1172\/JCI65907","article-title":"Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus in mice","volume":"123","author":"Look","year":"2013","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.nano.2014.12.003_bb0485","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.biomaterials.2013.10.046","article-title":"The nanomaterial-dependent modulation of dendritic cells and its potential influence on therapeutic immunosuppression in lupus","volume":"35","author":"Look","year":"2014","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.nano.2014.12.003_bb0490","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/art.30108","article-title":"Therapeutic potential of anti-interleukin-17A aptamer: suppression of interleukin-17A signaling and attenuation of autoimmunity in two mouse models","volume":"63","author":"Ishiguro","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.nano.2014.12.003_bb0495","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.molimm.2013.08.006","article-title":"A novel nanoparticle containing MOG peptide with BTLA induces T cell tolerance and prevents multiple sclerosis","volume":"57","author":"Yuan","year":"2013","journal-title":"Mol Immunol"},{"key":"10.1016\/j.nano.2014.12.003_bb0500","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/978-1-62703-586-6_3","article-title":"Therapeutic human monoclonal antibodies in inflammatory diseases","volume":"1060","author":"Kotsovilis","year":"2014","journal-title":"Methods Mol Biol"},{"issue":"9","key":"10.1016\/j.nano.2014.12.003_bb0505","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.2337\/db12-0049","article-title":"Rapamycin\/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function","volume":"61","author":"Long","year":"2012","journal-title":"Diabetes"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963415000088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963415000088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T14:16:42Z","timestamp":1566224202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963415000088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":101,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S1549963415000088"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2014.12.003","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic applications of nanomedicine in autoimmune diseases: From immunosuppression to tolerance induction","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2014.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}